| Document |
Document Title |
|
WO/2022/216709A1 |
This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiment...
|
|
WO/2022/214106A1 |
Disclosed are a naphthyl urea compound having anti-cancer effect, a preparation method therefor, and a use thereof. The naphthalene urea parent nucleus radical group contained therein having biological activity is further chemically modi...
|
|
WO/2022/214008A1 |
A compound having a structure of formula (I) or formula (II) and having the activity of inhibiting HPK1 kinase and a pharmaceutical composition comprising said compound and a use thereof in the prevention and/or treatment of cancer, tumo...
|
|
WO/2022/214606A1 |
The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the ...
|
|
WO/2022/216655A1 |
The present invention relates to (6-((octahydrocyclopenta[c]pyrrol-5- yl)amino)pyridazin-3-yl)benzamide (R2b is -C(O)N(RA1)(RA2) and N- (6-((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)
phenyl) carboxamide (R2b is -N(RB)C(O)R...
|
|
WO/2022/216098A1 |
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition for the prevention or treatment of diseases or disorders mediated by or associated with LRRK2, t...
|
|
WO/2022/216644A1 |
Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such...
|
|
WO/2022/214921A1 |
The present invention relates to an improved process for the preparation of intermediate compounds used in the preparation of Antihistamine agents. The present invention specifically relates to an improved process for the preparation of ...
|
|
WO/2022/216626A1 |
Described herein are hydroxypyridine HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascul...
|
|
WO/2022/214044A1 |
Disclosed are compounds as represented by formulas (A) to (D) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof, the definitions of the groups in the formulas being detailed in the description. Further dis...
|
|
WO/2022/207482A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein X, Y1, Y2, R1, R2, R7, and n are as defined herein. The invention further relates to herbicidal compositions which c...
|
|
WO/2022/212296A1 |
A compound of Formula (I), (I'), (II), (II'), (III), or (IV) or a pharmaceutically-acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using...
|
|
WO/2022/206684A1 |
Provided are a series of Se-containing pyrazine compounds and an application thereof. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
|
WO/2022/205587A1 |
Disclosed in embodiments of the present invention are an organic compound and a production method therefor, and a display panel. The general formula of the organic compound is (I), wherein Ar includes any one of or a combination of some ...
|
|
WO/2022/206797A1 |
Compounds of formula A, a method for using said compounds as an EGFR inhibitor, and a pharmaceutical composition comprising said compounds. The compounds can be used to treat, prevent or ameliorate diseases or conditions such as cancers ...
|
|
WO/2022/212818A1 |
Described are 6-aryl [1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and com...
|
|
WO/2022/212489A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2022/212707A1 |
The present invention relates to antiviral agents according to Formula (I) and their use in the treatment of viral infection.
|
|
WO/2022/212194A1 |
Compounds of formula (I), wherein the variable substituents are defined herein.
|
|
WO/2022/210524A1 |
The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation. This problem is solved by a nitrogen-containing compound represented by general formula (I...
|
|
WO/2022/206939A1 |
Provided is a heterocyclic compound serving as an FGFR inhibitor, and specifically, disclosed are a compound represented by formula (I), and a stereoisomer or pharmaceutically acceptable salt thereof.
|
|
WO/2022/208454A1 |
The present disclosure relates to novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food for the prevention or treatment of cancer, containing the same as ...
|
|
WO/2022/208382A1 |
The present invention provides a compound of chemical formula 1, a compound of chemical formula 3, compound [212], compound [224], or compound [228], a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, ...
|
|
WO/2022/212488A1 |
The present disclosure provides certain bicyclic heteroaryl phosphonate compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and condi...
|
|
WO/2022/206350A1 |
Provided herein are inhibitors of methionine aminopeptidase 2 (MetAP-2) and pharmaceutical compositions thereof, and their use and methods of treatment, reduction or prevention of certain diseases or conditions associated with MetAP-2 (e...
|
|
WO/2022/206937A1 |
Provided are a new crystal form of hydrochloride of (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolid
in-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide, a preparation method therefor, a pharmaceutical composition containing the compoun...
|
|
WO/2022/212815A1 |
Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treat...
|
|
WO/2022/207462A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/206742A1 |
The present invention belongs to the technical field of medicine synthesis, and in particular relates to a method for synthesizing a thiohydantoin derivative by means of a one-step method. By means of taking three components, i.e., an am...
|
|
WO/2022/211518A1 |
The present invention pertains to a novel compound and a use thereof in treating psoriasis, asthma, or systemic lupus erythematosus. A pharmaceutical composition containing the novel compound of the present invention can not only control...
|
|
WO/2022/206800A1 |
A tetrahydronaphthyridine compound (I) crystal form and salt form and preparation methods therefor, and applications thereof in drugs for treating related diseases.
|
|
WO/2022/206964A1 |
Provided are a compound represented by formula (I), a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or co-crystal, or a pharmaceutical composition comprising same, and a use t...
|
|
WO/2022/204906A1 |
A protein crystallization nucleating agent and a preparation method for the protein crystallization nucleating agent. The nucleating agent has a hydrophobic three-dimensional porous structure. In the hydrophobic three-dimensional porous ...
|
|
WO/2022/207935A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for mod...
|
|
WO/2022/206705A1 |
The present invention provides a heterocyclic compound as a TYK2 pseudokinase (JH2) domain inhibitor, a synthetic method, and use. In particular, the present invention provides a heterocyclic compound as represented by formula I, or a ph...
|
|
WO/2022/208149A1 |
The present disclosure relates to a process for preparing Chlorantraniliprole. The process is simple, efficient and economical. The process of the present disclosure provides a comparatively higher yield of Chlorantraniliprole with great...
|
|
WO/2022/211573A1 |
The present invention relates to a pharmaceutical composition for preventing and treating cancers, including lung cancer, caused by abnormal cell growth, the pharmaceutical composition containing, as active ingredients, a novel trisubsti...
|
|
WO/2022/212638A1 |
Compounds of formula (I) useful as inhibitors of ADAMTS-5 and/or ADAMTS-4, pharmaceutical compositions thereof, and use of them as therapeutic agents for the treatment of diseases involving degradation of cartilage or disruption of carti...
|
|
WO/2022/208262A1 |
The invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q' and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating corona...
|
|
WO/2022/212806A1 |
Provided herein are methods of treating a cancer comprising administering an EGFR degrader to a patient suffering therefrom and subjecting the patient to radiation. The cancer can express mutant, overexpressed or overly activated EGFR, m...
|
|
WO/2022/206737A1 |
The present disclosure relates to a tetrahydronaphthalene compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a tetrahydronaphthalene compound as represented by gen...
|
|
WO/2022/212819A1 |
Disclosed herein are (6-(2H-indazol-5-yl)pyridazin-3-yl)octahydrocyclopenta[c]pyr
rol-5- amine compounds, useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compo...
|
|
WO/2022/204475A1 |
Provided herein are fluorogenic sensors which can be used to detect targets (e.g., antigens). In general, the fluorogenic sensors provided herein comprise a protein (e.g., antibody, nanobody, mini-protein) and a fluorogenic small molecul...
|
|
WO/2022/198361A1 |
Disclosed is a novel crystal form of dabigatran etexilate ethyl ester hydrochloride, the X-ray powder diffraction pattern thereof having diffraction peaks at 2θ ± 0.2°, and 2θ is at least selected from any one of 5.42 ± 0.2°, 9.08 ...
|
|
WO/2022/199656A1 |
Disclosed are a pharmaceutical combination, a kit containing same, and the use thereof in the preparation of a drug for treating breast cancer. The pharmaceutical combination comprises a first active ingredient and a second active ingred...
|
|
WO/2022/203466A1 |
The present invention provides a pyrimidine compound of chemical formula 1, a pharmaceutical composition containing same for preventing or treating a LRRK2-mediated or related disease (for example, Parkinson's disease), and a method for ...
|
|
WO/2022/199375A1 |
Disclosed in the present invention are a pharmaceutical composition of a quinazoline compound and a preparation method therefor. The pharmaceutical composition of the present invention contains a substance X and a pharmaceutical excipien...
|
|
WO/2022/200444A1 |
The present invention relates to a new process for preparing 5-{5-chloro-2-[(3S)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1H)-carbo
nyl]phenyl}-1,2-dimethyl- 1H-pyrrole-3 -carboxylic acid derivatives and its application for ...
|
|
WO/2022/199289A1 |
Disclosed are a novel androgen receptor degrader having the structure represented by general formula I or general formula II, a preparation method, and a medical use. Pharmacological experiments have proved that the compound has good ant...
|
